Gut microbe metabolite found to modulate heart disease risk through β2-adrenergic receptors

Study identifies phenylacetylglutamine (PAGln), a gut microbiome metabolite, as a novel allosteric modulator of β2-adrenergic receptors, offering insights into its role in cardiovascular disease (CVD) risk.

Almirall, Absci partner on dermatological drug development

Share this article The companies will develop treatment candidates for two targets in dermatology. Credit: Chokniti-Studio / Shutterstock.com. Almirall has entered an artificial intelligence (AI)-driven drug

November 15, 2023

Harmony Biosciences buys small epilepsy biotech for $35M, plus milestones

Rare neurological disease drug developer Harmony Biosciences acquired Epygenix Therapeutics and its pipeline of treatments for rare epilepsy conditions. Harmony paid $35 million upfront, and

May 1, 2024

Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer

MADRID — Chemotherapy’s generation-long dominance in first-line advanced urothelial cancer ended with a resounding victory for the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab

October 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.